Gyre Therapeutics, Inc. GYRE Noncash Lease Expense
Noncash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept gyre:NoncashLeaseExpense.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s noncash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s noncash lease expense?
- Gyre Therapeutics, Inc. (GYRE) reported noncash lease expense of $217K in Q1 2026.
- How has Gyre Therapeutics, Inc.'s noncash lease expense changed year-over-year?
- Gyre Therapeutics, Inc.'s noncash lease expense increased by 10.2% year-over-year, from $197K to $217K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s noncash lease expense?
- Over 3 years (2022 to 2025), Gyre Therapeutics, Inc.'s noncash lease expense has grown at a 24.4% compound annual growth rate (CAGR), from $404K to $777K.
- What does noncash lease expense mean?
- Represents the portion of lease expenses that does not involve an immediate cash outflow, typically associated with the amortization of right-of-use assets. This metric helps investors understand the non-cash impact of operating leases on the company's reported profitability. It is essential for reconciling net income to cash flow from operations.